Home › Funds › Parkman Healthcare Partners LLC › AGIO
Parkman Healthcare Partners LLC position in AGIO
AGIOS PHARMACEUTICALS INC · Health Care
Parkman Healthcare Partners LLC reported holding 633,312 shares of AGIO (AGIOS PHARMACEUTICALS INC) in its Q3 2026 13F filing — a position valued at US$21.1M, representing 1.90% of its reported portfolio and ranking #12 among its reported holdings. Parkman Healthcare Partners LLC has disclosed AGIO holdings in 7 of the last 10 reported quarters, going back to Q2 2024.
Last updated: 2026-11-16 · Source: SEC EDGAR Form 13F-HR
How Parkman Healthcare Partners LLC's AGIO position evolved
Parkman Healthcare Partners LLC first disclosed a stake in AGIO in Q2 2024 at 446,416 shares (US$19.2M). The position peaked in Q2 2026 at 669,046 shares, worth US$24.8M. Across 7 filings, Parkman Healthcare Partners LLC increased the stake 2 time(s), trimmed it 3 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 633,312 shares valued at US$21.1M — a reduction of -35,734 shares quarter over quarter.. Notable position changes include a 36% trim in Q3 2024 (shares fell 26% over the following quarter), a 305% increase in Q1 2026 (shares rose 10% over the following quarter), a 66% increase in Q2 2026 (shares fell 10% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q2 2024 | 446.42K | $19.25M | New |
| Q3 2024 | 285.10K | $12.67M | Reduce |
| Q3 2025 | 100.38K | $4.03M | New |
| Q4 2025 | 99.60K | $2.71M | Reduce |
| Q1 2026 | 403.52K | $13.65M | Add |
| Q2 2026 | 669.05K | $24.83M | Add |
| Q3 2026 | 633.31K | $21.06M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AGIO and 13F data
AGIO (AGIOS PHARMACEUTICALS INC) is a Health Care company. 29 other funds we track also report a position in AGIO — the largest reported positions include Farallon Capital Management (US$219.6M), FARALLON CAPITAL MANAGEMENT, L.L.C. (US$197.5M), Lynx1 Capital Management LP (US$126.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AGIO
- Farallon Capital Management 5.92M sh · $219.59M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 5.94M sh · $197.49M · Q3 2026
- Lynx1 Capital Management LP 3.41M sh · $126.51M · Q2 2026
- ARMISTICE CAPITAL, LLC 2.58M sh · $85.72M · Q3 2026
- Erste Asset Management GmbH 1.80M sh · $60.10M · Q3 2026
- ADAR1 Capital Management, LLC 1.14M sh · $37.89M · Q3 2026
- Foresite Capital Management VI LLC 785.00K sh · $29.13M · Q2 2026
More on Parkman Healthcare Partners LLC
FAQ
How long has Parkman Healthcare Partners LLC held AGIO?
Parkman Healthcare Partners LLC has disclosed AGIO holdings in 7 of the last 10 reported quarters, going back to Q2 2024.
What is Parkman Healthcare Partners LLC's current position in AGIO?
As of Q3 2026, Parkman Healthcare Partners LLC holds 633.31K shares of AGIO (AGIOS PHARMACEUTICALS INC), valued at $21.06M, representing 1.90% of its reported portfolio and ranking #12.
Has Parkman Healthcare Partners LLC been buying or selling AGIO?
In the latest 13F filing (Q3 2026), Parkman Healthcare Partners LLC reduced its position in AGIO. The position peaked in Q2 2026 at 669.05K shares.
Which other funds hold AGIO?
Other major institutional holders of AGIO include Farallon Capital Management, FARALLON CAPITAL MANAGEMENT, L.L.C., Lynx1 Capital Management LP, among 29 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.